BUB1B promotes multiple myeloma cell proliferation through CDC20/CCNB axis

Med Oncol. 2015 Mar;32(3):81. doi: 10.1007/s12032-015-0542-x. Epub 2015 Feb 20.

Abstract

Multiple myeloma (MM) is the second most common hematopoietic malignancy characterized by plasma cell proliferative disorder. In this study, we disclosed that expression of BUB1B significantly increased in high-risk myeloma patients especially in the most aggressive myeloma genetic subgroups of proliferation. Increased BUB1B expression promotes MM cell proliferation. Mechanism study showed that BUB1B expression was highly correlated to CDC20 and CCNB1/2 expression in MM cells, leading to increased MM cell proliferation. Therefore, BUB1B may be a potential target for MM treatment especially for high-risk MM patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bortezomib / pharmacology
  • Cdc20 Proteins / metabolism*
  • Cell Line, Tumor
  • Cell Proliferation / genetics
  • Cyclin B1 / metabolism*
  • Drug Resistance, Neoplasm / genetics
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Kaplan-Meier Estimate
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / genetics
  • Multiple Myeloma / metabolism*
  • Multiple Myeloma / mortality
  • Multiple Myeloma / pathology*
  • Protein Serine-Threonine Kinases / genetics
  • Protein Serine-Threonine Kinases / metabolism*

Substances

  • CCNB1 protein, human
  • Cdc20 Proteins
  • Cyclin B1
  • CDC20 protein, human
  • Bortezomib
  • BUB1 protein, human
  • Protein Serine-Threonine Kinases